CD44v10, osteopontin and lymphoma growth retardation by a CD44v10-specific antibody

Immunology and Cell Biology

Volumn 92, Issue 8, 2014, Pages 709-720

  Megaptche, Amelie Pajip ^a   Erb, Ulrike ^a   Büchler, Markus Wolfgang ^a   Zöller, Margot ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD44V ANTIGEN; OSTEOPONTIN; ANTINEOPLASTIC AGENT; CD44V10 ANTIGEN; HERMES ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; INFLAMMATION; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTIBODY SPECIFICITY; APOPTOSIS; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; OSTEOPONTIN; T-LYMPHOCYTE SUBSETS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926205370     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.47     Document Type: Article

References (65)

1. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56: 1063-1072.
2. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
3. Hertweck MK, Erdfelder F, Kreuzer KA. CD44 in hematological neoplasias. Ann Hematol 2011; 90: 493-508.
4. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
5. Ghosh SC, Neslihan Alpay S, Klostergaard J. CD44: a validated target for improved delivery of cancer therapeutics. Exp Opin Ther Targets 2012; 16: 635-650.
6. Platt VM, Szoka Jr. FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharmacol 2008; 5: 474-486.
7. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
8. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005; 106: 1901-1910.
9. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-539.
10. Liu J, Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol 2006; 3: 359-365.
11. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174.
12. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175-1180.
13. Siegelman MH, Stanescu D, Estess P. The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion. J Clin Invest 2000; 105: 683-691.
14. Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34\+ stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-2989.
15. Davids MS, Burger JA. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol 2012; 3: 2-3.
16. Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008; 18: 251-259.
17. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276-287.
18. Lamontagne CA, Grandbois M. PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells. Exp Cell Res 2008; 314: 227-236.
19. Oliferenko S, Kaverina I, Small JV, Huber LA. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. J Cell Biol 2000; 148: 1159-1164.
20. Liu D, Sy MS. Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. J Immunol 1997; 159: 2702-2711.
21. Föger N, Marhaba R, Zöller M. Raft associated interaction of CD44 with the cytoskeleton. J Cell Sci 2001; 114: 1169-1178.
22. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128: 687-698.
23. Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme? Adv Cancer Res 2008; 101: 63-92.
24. Weber GF. Molecular mechanisms of metastasis. Cancer Lett 2008; 270: 181-190.
25. El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 2008; 13: 4276-4284.
26. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 2007; 282: 19426-19441.
27. Matzke A, Herrlich P, Ponta H, Orian-Rousseau V. A five-amino-acid peptide blocks Met-and Ron-dependent cell migration. Cancer Res 2005; 65: 6105-6110.
28. Toole BP, Slomiany MG. Hyaluronan CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Update 2008; 11: 110-121.
29. Liu CM, Chang CH, Yu CH, Hsu CC, Huang LL. Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling. Cell Tissue Res 2009; 336: 465-475.
30. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010; 70: 2455-2464.
31. Avin E, Haimovich J, Hollander N. Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma. J Immunol 2004; 173: 4736-4743.
32. Christ O, Günthert U, Schmidt DS, Zöller M. Allogeneic reconstitution after nonmyeloablative conditioning: mitigation of graft-versus-host and host-versus-graft reactivity by anti-CD44v6. J Leuk Biol 2002; 71: 33-46.
33. Zöller M, Föhr N, Herrmann K. Treatment of mice with anti-CD44 after allogeneic bone marrow cell transplantation is lethal. J Leuk Biol 1998; 63: 175-189.
34. Ghazi-Visser L, Laman JD, Nagel S, van Meurs M, van Riel D, Tzankov A et al. CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells. FASEB J 2013; 27: 3683-3701.
35. Rösel M, Khaldoyanidi S, Zawadzki V, Zöller M. Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol 1999; 27: 698-711.
36. Rösel M, Föger N, Zöller M. Involvement of CD44 exon v10 in B-cell activation. Tissue Antigens 1998; 52: 99-113.
37. Zöller M. CD44v10 in hematopoiesis and stem cell mobilization. Leuk Lymph 2000; 38: 463-480.
38. Rösel M, Seiter S, Zöller M. CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol 1997; 171: 305-317.
39. Endo K, Mizusawa N, Hirano H, Shimamura T. Expression of CD44 variant isoforms in leukocytes of the joint fluid of rheumatoid arthritis patients and the effect of steroids. Methods Find Exp Clin Pharmacol 1998; 20: 709-717.
40. Freyschmidt-Paul P, Seiter S, Zoller M, König A, Ziegler A, Sundberg JP et al. Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol 2000; 115: 653-657.
41. Zöller M, Gupta P, Marhaba R, Vitacolonna M, Freyschmidt-Paul P. Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases. J Leuk Biol 2007; 82: 57-71.
42. Seiter S, Schadendorf D, Tilgen W, Zöller M. CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopath 1998; 89: 79-93.
43. Wagner SN, Wagner C, Reinhold U, Funk R, Zöller M, Goos M. Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes. J Invest Dermatol 1998; 111: 464-471.
44. Zalewski B, Stasiak-Barmuta A, Guziń ska-Ustymowicz K, Cepowicz D, Gryko M. Molecule CD44 variant 10 expression in lymphocytes infiltrating tumour tissues and epithelial cells in patients with colorectal cancer. Rocz Akad Med Bialymst 2004; 49 (Suppl 1), 91-93.
45. Weimann TK, Wagner C, Funk R, Hirche H, Goos M, Wagner SN. Hyaluronanindependent adhesion of CD44H\+ and CD44v10\+ lymphocytes to dermal microvascular endothelial cells and keratinocytes. J Invest Dermatol 2001; 117: 949-957.
46. Singleton PA, Dudek SM, Ma SF, Garcia JG. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006; 281: 34381-34393.
47. Beham-Schmid C, Heider KH, Hoefler G, Zatloukal K. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse. J Pathol 1998; 186: 383-389.
48. Asosingh K, Günthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001; 61: 2862-2865.
49. Seiter S, Schadendorf D, Herrmann K, Schneider M, Rösel M, Arch R et al. Expression of CD44 variant isoforms in malignant melanoma. Clin Cancer Res 1996; 2: 447-456.
50. Yoshinari C, Mizusawa N, Byers HR, Akasaka T. CD44 variant isoform CD44v10 expression of human melanoma cell lines is upregulated by hyaluronate and correlates with migration. Melanoma Res 1999; 9: 223-231.
51. Zawadzki V, Perschl A, Rösel M, Hekele A, Zöller M. Blockade of metastasis formation by CD44-receptor globulin. Int J Cancer 1998; 75: 919-924.
52. Akisik E, Bavbek S, Dalay N. CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res 2002; 8: 36-40.
53. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-184.
54. Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B et al. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 2012; 3: 91.
55. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012; 4: 511-527.
56. Kanayama M, Morimoto J, Matsui Y, Ikesue M, Danzaki K, Kurotaki D et al. a9b1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol 2011; 187: 5851-5864.
57. Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, Scatena M. Osteopontin mediates macrophage chemotaxis via a4 and a9 integrins and survival via the a4 integrin. J Cell Biochem 2013; 114: 1194-1202.
58. Zou C, Luo Q, Qin J, Shi Y, Yang L, Ju B et al. Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin b1, FAK, and ERK pathways. Cell Biochem Biophys 2013; 65: 455-462.
59. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011; 6: e24217.
60. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-226.
61. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007; 67: 2089-2097.
62. O'Regan AW, Chupp GL, Lowry JA, Götschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokinelike properties in vitro. J Immunol 1999; 162: 1024-1031.
63. Zheng Y, Wang Z, Deng L, Yuan X, Ma Y, Zhang G et al. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. Eur J Immunol 2012; 42: 2803-2814.
64. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol 2009; 9: 137-141.
65. Reiter H. Effect of thymidine on the survival of mice with EL4 tumors. Cancer Res 1979; 39: 4856-4860